Mateon Therapeutics, Inc.

48 articles with Mateon Therapeutics, Inc.

• FDA Granted Pediatric Disease Designation for OXi-4503-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients

  9/16/2020

  Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that the US Food and Drug Administration (FDA) granted our request and designate OXi4503 (combretastatin A1-diphosphate; CA1P) for treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients as a drug for a “rare pediatric disease,” as defined in section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act

• Mateon’s Global Study for Artemisinin Intervention Against COVID-19 Cleared for Patient Enrollment in India

  9/14/2020

  Mateon Therapeutics “Mateon”, a leading developer of TGF-β therapeutics for oncology and COVID-19, announced that its global study based on its ARTI-19 protocol for Artemisinin Intervention against COVID-19 has been cleared for patient enrollment in India.

• 

  Biopharma Update on the Novel Coronavirus: September 14

  9/14/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.

• Mateon Therapeutics Closes $2.0 Million Financing

  7/27/2020

  Mateon Therapeutics announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc..

• Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19

  7/20/2020

  Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research Alliance of Tanzania.

• Mateon Therapeutics to fund observational studies of Artemisinin in developing countries

  7/13/2020

  Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.

• Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19

  6/24/2020

  Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s 

• 

  Biopharma Update on the Novel Coronavirus: June 24

  6/24/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.

• Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients

  6/23/2020

  Mateon Therapeutics, a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101.

• Mateon and GMP Completed Research and Service AgreementMateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19

  6/22/2020

  Mateon Therapeutics, Inc. (“Mateon” or the “Company”)  (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement (the “Agreement”) entered on February 3, 2020 and modified on March 22, 2020.

• Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO

  6/10/2020

  The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of its first milestone and milestone payment by Autotelic BIO. OT-101 and IL-2 demonstrated good synergy against tumor xenograft model as an immune-oncology therapy. OT-101/IL-2 combination will advance to Phase 1 clinical development. AGOURA HILLS, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Mateo

• Mateon Announces an Expansion to its Pharmaceutical Manufacturing AI Camera Grid by Including Contact Tracing to Ensure Worker Safety

  6/8/2020

  Mateon Therapeutics, Inc. – Mateon announced that EdgePoint AI, a division within Mateon, announced its decision to expand its manufacturing AI vision camera grid to encompass a contact tracing application which will monitor the spread of COVID-19 indoors.

• Mateon Provides Update on OT-101

  6/1/2020

  Mateon Therapeutics Inc.  (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun, Vuong Trieu.  Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children.  Clin Res Pediatr 2020; 3(1): 1-3 Fatih M. Uckun, Larn Hwang, Vuong Trieu. Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in

• FDA Grants Pediatric Disease Designation for Mateon’s CA4PTreatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients

  5/5/2020

  Mateon Therapeutics Inc. announced that the US Food and Drug Administration granted Rare Pediatric Disease Designation for CA4P/ Fosbretabulin for the treatment of of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients as a drug for a “rare pediatric disease”.

• 

  Clinical Catch-Up: April 27-May 1

  5/4/2020

  There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.

• Mateon Provides Update on its R&D Effort Against COVID-19

  4/30/2020

  Mateon Therapeutics Inc. report several peer-reviewed publications derived from its R&D effort against COVID-19..

• Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients

  4/27/2020

  Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to study its investigational drug, OT-101, for the treatment of COVID-19 pandemic. The proposed randomized, double-blind, placebo-controlled Phase 2 study is intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia in th

• 

  Biopharma Update on the Novel Coronavirus: April 27

  4/27/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.

• Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin

  4/8/2020

  In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 Artemisinin complements OT-101 which continues to demonstrate potent activity against SARS-CoV-2 and expands the company’s intellectual property portfolio AGOURA HILLS, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) today announced that its COVID-19 directed antiviral screening

• Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19

  4/6/2020

  Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to development OT-101, a TGF-β antisense drug candidate, announced today that Mateon has delivered the requisite testing results to Golden Mountain Partners (GMP) confirming the applicability and potential use of OT-101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of >500